Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK posts promising results from gonorrhoea treatment trial
(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies. The FTSE 100 pharmaceutical giant said the trial's primary endpoint, microbiological response at the test-of-cure (ToC) visit, showed a 92.6% success rate, rendering it non-inferior to the leading combination therapy comprising intramuscular (IM) ceftriaxone and oral azithromycin.
Notably, gepotidacin's safety profile mirrored previous phase one and two trials, with gastrointestinal adverse events being the most commonly reported, predominantly mild or moderate in nature.
Gonorrhoea, a prevalent global concern, sees around 82 million new cases annually worldwide.
In the United States alone, reported cases surged 118% from 2009 to 2021, as per the CDC, with nearly half displaying resistance to at least one antibiotic.
The infection, caused by neisseria gonorrhoeae bacteria, poses risks including infertility and heightened vulnerability to HIV.
Beyond its application in gonorrhoea, GSK said gepotidacin held promise for addressing uncomplicated urinary tract infections (uUTI).
Positive phase three data from the EAGLE-2 and EAGLE-3 trials, disclosed at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April last year and published in the Lancet, underscored its potential significance as the first oral antibiotic class in uUTI in over two decades.
The company said the development of gepotidacin had received federal support, notably from the US Department of Health and Human Services and the Defense Threat Reduction Agency.
"These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide including drug resistant infections," said GSK's senior vice-president of development, Chris Corsico.
"The imperative for innovative treatments has never been clearer.
"We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs."
At 0808 BST, GSK shares were down 0.9% at 1,596p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.